LEO PHARMA A/S: Financial statements 2017
CVR: 56759514
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 10,481,000,000 and a net result of DKK 1,381,000,000 compared with DKK 743,000,000 the year before. That is an increase of 42.4% compared with the year before. The profit margin was 13.2%. Equity in the 2017 report amounted to DKK 8,277,000,000. The solvency ratio was 56.7%.
- Revenue
- DKK 10,481,000,000
- Gross Profit
- DKK 7,543,000,000
- Profit/Loss
- DKK 1,381,000,000
- Equity
- DKK 8,277,000,000
- Total Assets
- DKK 14,593,000,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 10.5 mia. | 7.5 mia. | 1.4 mia. | 8.3 mia. | - |
| 2016 | 7.4 mia. | 2.7 mia. | 743 mio. | 25.2 mia. | 5170 |
| 2015 | 6.9 mia. | 2 mia. | 645 mio. | 25.3 mia. | 4813 |
| 2014 | 6.6 mia. | - | 1.5 mia. | 24.5 mia. | 4712 |
| 2013 | 5.8 mia. | - | 1.2 mia. | 23.1 mia. | 4733 |
Official annual report
Keep an eye on LEO PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of May 23, 2017, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of LEO PHARMA A/S.
As of May 23, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2016. Revenue came to DKK 7,360,000,000, and the net result was DKK 743,000,000.
As of March 30, 2017, Cristina Patricia Lage has joined the board of directors of LEO PHARMA A/S.
As of March 30, 2017, Johannes Gerardus Joseph van de Winkel has joined the board of directors of LEO PHARMA A/S.
As of March 30, 2017, Jens Bo Olesen has left the board of directors of LEO PHARMA A/S.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.